Moderna to Host R&D Day on September 12, 2019
August 29 2019 - 8:00AM
Business Wire
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology
company pioneering messenger RNA (mRNA) therapeutics and vaccines
to create a new generation of transformative medicines for
patients, today announced that it will host its third annual
R&D Day for analysts and investors at 8:00 a.m. ET on Thursday,
September 12 at the JW Marriott Essex House in New York City.
Moderna’s R&D Day will include presentations from Stéphane
Bancel, chief executive officer, Tal Zaks M.D., Ph.D., chief
medical officer and key opinion leaders with a focus on the
Company’s clinical development pipeline.
A live webcast will be available under “Events &
Presentations” in the Investors section of the Moderna website at
https://investors.modernatx.com. A replay of the webcast will be
archived on Moderna’s website for 30 days following the
presentation.
About Moderna Moderna is advancing messenger RNA (mRNA)
science to create a new class of transformative medicines for
patients. mRNA medicines are designed to direct the body’s cells to
produce intracellular, membrane or secreted proteins that can have
a therapeutic or preventive benefit and have the potential to
address a broad spectrum of diseases. Moderna’s platform builds on
continuous advances in basic and applied mRNA science, delivery
technology and manufacturing, providing the Company the capability
to pursue in parallel a robust pipeline of new development
candidates. Moderna is developing therapeutics and vaccines for
infectious diseases, immuno-oncology, rare diseases and
cardiovascular diseases, independently and with strategic
collaborators.
Headquartered in Cambridge, Mass., Moderna currently has
strategic alliances for development programs with AstraZeneca, Plc.
and Merck, Inc., as well as the Defense Advanced Research Projects
Agency (DARPA), an agency of the U.S. Department of Defense; the
Biomedical Advanced Research and Development Authority (BARDA), a
division of the Office of the Assistant Secretary for Preparedness
and Response (ASPR) within the U.S. Department of Health and Human
Services (HHS). Moderna has been ranked in the top ten of Science’s
list of top biopharma industry employers for the past four years.
To learn more, visit www.modernatx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190829005181/en/
Investors: Lavina Talukdar Head of Investor Relations
617-209-5834 Lavina.Talukdar@modernatx.com Media: Colleen
Hussey Senior Manager, Corporate Communications 203-470-5620
Colleen.Hussey@modernatx.com
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Apr 2023 to Apr 2024